Systemic involvement of acute generalized exanthematous pustulosis: A retrospective study on 58 patients

British Journal of Dermatology

Volumn 169, Issue 6, 2013, Pages 1223-1232

  Hotz, C ^a   Valeyrie Allanore, L ^a   Haddad, C ^a   Bouvresse, S ^a   Ortonne, N ^a   Duong, T A ^a   Ingen Housz Oro, S ^a   Roujeau, J C ^a   Wolkenstein, P ^a   Chosidow, O ^a,b  

^a HENRI MONDOR HOSPITAL   (France)

^b INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACEPROMAZINE; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ATENOLOL; CEFOTAXIME; CEFPODOXIME; CELECOXIB; CLOXACILLIN; CYAMEMAZINE; DEXTROPROPOXYPHENE; DILTIAZEM; GALANTAMINE; GRISEOFULVIN; HYDROXYCHLOROQUINE; IBUPROFEN; KETOPROFEN; LOXAPINE; MEPROBAMATE; NIFLUMIC ACID; NITROFURANTOIN; PARACETAMOL; PAROXETINE; PHOLCODINE; PIROXICAM; PRISTINAMYCIN; RISPERIDONE; STEROID; TERBINAFINE; TIAPROFENIC ACID; UNINDEXED DRUG;

ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS; ACUTE KIDNEY FAILURE; ADULT; AGED; AGRANULOCYTOSIS; ARTICLE; BONE MARROW BIOPSY; BONE MARROW DISEASE; CHEILITIS; CLINICAL FEATURE; CONJUNCTIVITIS; DISEASE SEVERITY; DRUG RECHALLENGE; FEMALE; HOSPITAL PATIENT; HUMAN; KIDNEY DISEASE; KIDNEY FAILURE; LENGTH OF STAY; LIVER DISEASE; LIVER FUNCTION TEST; LUNG DISEASE; LUNG LAVAGE; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; NEUTROPHIL COUNT; OUTCOME ASSESSMENT; OXYGEN THERAPY; PALLIATIVE THERAPY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECURRENT DISEASE; RESPIRATORY DISTRESS; RETROSPECTIVE STUDY; STEROID THERAPY; SYSTEMIC DISEASE; ADULT RESPIRATORY DISTRESS SYNDROME; COMPLICATION; CYTOLOGY; LEUKOCYTE COUNT; MIDDLE AGED; NEUTROPHIL; PATHOLOGY; VERY ELDERLY; YOUNG ADULT;

ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS; ADULT; AGED; AGED, 80 AND OVER; BRONCHOALVEOLAR LAVAGE FLUID; HUMANS; LEUKOCYTE COUNT; LIVER DISEASES; MALE; MIDDLE AGED; NEUTROPHILS; RENAL INSUFFICIENCY; RESPIRATORY DISTRESS SYNDROME, ADULT; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84889024707     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12502     Document Type: Article

References (37)

1. Roujeau JC, Bioulac-Sage P, Bourseau C, et al,. Acute generalized exanthematous pustulosis. Analysis of 63 cases. Arch Dermatol 1991; 127: 1333-8.
2. Beylot C, Doutre MS, Beylot-Barry M,. Acute generalized exanthematous pustulosis. Semin Cutan Med Surg 1996; 15: 244-9.
3. Roujeau J-C,. Clinical heterogeneity of drug hypersensitivity. Toxicology 2005; 209: 123-9.
4. Sidoroff A, Dunant A, Viboud C, et al,. Risk factors for acute generalized exanthematous pustulosis (AGEP)-results of a multinational case-control study (EuroSCAR). Br J Dermatol 2007; 157: 989-96.
5. Halevy S, Kardaun SH, Davidovici B, Wechsler J,. The spectrum of histopathological features in acute generalized exanthematous pustulosis: a study of 102 cases. Br J Dermatol 2010; 163: 1245-52.
6. Burrows NP, Russell Jones RR,. Pustular drug eruptions: a histopathological spectrum. Histopathology 1993; 22: 569-73.
7. Kardaun SH, Sidoroff A, Valeyrie-Allanore L, et al,. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatol 2007; 156: 609-11.
8. Sidoroff A, Halevy S, Bavinck JN, et al,. Acute generalized exanthematous pustulosis (AGEP)-a clinical reaction pattern. J Cutan Pathol 2001; 28: 113-19.
9. Ben Salem C, Fathallah N, Saidi W, et al,. Acute generalized exanthematous pustulosis as a manifestation of anticonvulsant hypersensitivity syndrome. Ann Pharmacother 2010; 44: 1681-2.
10. Leclair M-A, Maynard B, St-Pierre C,. Acute generalized exanthematous pustulosis with severe organ dysfunction. CMAJ 2009; 181: 393-6.
11. Brandenburg VM, Kurts C, Eitner F, et al,. Acute reversible renal failure in acute generalized exanthematous pustulosis. Nephrol Dial Transplant 2002; 17: 1857-8.
12. Lesterhuis WJ, Tjioe M, Stumpenhausen GA, Van Crevel R,. Acute generalised exanthematous pustulosis mimicking septic shock. Am J Med 2004; 116: 574-5.
13. Byerly FL, Nelson KC, Granko RP, et al,. Valdecoxib-associated acute generalized exanthematous pustulosis. Burns 2005; 31: 383-7.
14. Begaud B,. Standardized assessment of adverse drug reactions: the method used in France. Special workshop-clinical. Drug Inf J 1984; 18: 275-81.
15. Bellomo R, Ronco C, Kellum JA, et al,. Acute renal failure-definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004; 8: R204-12.
16. Mehta RL, Kellum JA, Shah SV, et al,. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007; 11: R31.
17. Bouvresse S, Valeyrie-Allanore L, Ortonne N, et al,. Toxic epidermal necrolysis, DRESS, AGEP: do overlap cases exist? Orphanet J Rare Dis 2012; 7: 72.
18. Britschgi M, Steiner UC, Schmid S, et al,. T-cell involvement in drug-induced acute generalized exanthematous pustulosis. J Clin Invest 2001; 107: 1433-41.
19. Britschgi M, Pichler WJ,. Acute generalized exanthematous pustulosis, a clue to neutrophil-mediated inflammatory processes orchestrated by T cells. Curr Opin Allergy Clin Immunol 2002; 2: 325-31.
20. Schaerli P, Britschgi M, Keller M, et al,. Characterization of human T cells that regulate neutrophilic skin inflammation. J Immunol 2004; 173: 2151-8.
21. Speeckaert MM, Speeckaert R, Lambert J, Brochez L,. Acute generalized exanthematous pustulosis: an overview of the clinical, immunological and diagnostic concepts. Eur J Dermatol 2010; 20: 425-33.
22. Halevy S,. Acute generalized exanthematous pustulosis. Curr Opin Allergy Clin Immunol 2009; 9: 322-8.
23. Sonnenberg GF, Fouser LA, Artis D,. Border patrol: regulation of immunity, inflammation and tissue homeostasis at barrier surfaces by IL-22. Nat Immunol 2011; 12: 383-90.
24. Wolk K, Haugen HS, Xu W, et al,. IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-gamma are not. J Mol Med 2009; 87: 523-36.
25. Kabashima R, Sugita K, Sawada Y,. Increased circulating Th17 frequencies and serum IL-22 levels in patients with acute generalized exanthematous pustulosis. J Eur Acad Dermatol Venereol 2011; 25: 485-8.
26. Allez M, Roux ME, Bertheau P, et al,. Recurrent cholestatic jaundice associated with generalized pustular psoriasis: evidence for a neutrophilic cholangitis. J Hepatol 2000; 33: 160-2.
27. Viguier M, Allez M, Zagdanski A-M, et al,. High frequency of cholestasis in generalized pustular psoriasis: evidence for neutrophilic involvement of the biliary tract. Hepatology 2004; 40: 452-8.
28. Kawana S, Nishiyama S,. Pustular psoriasis and aseptic purulent arthritis: possible role of leukotrienes B4 and C4 in a flare of synovitis. Dermatology (Basel) 1995; 190: 35-8.
29. Kluger N, Bessis D, Guillot B, Girard C,. Acute respiratory distress syndrome complicating generalized pustular psoriasis (psoriasis-associated aseptic pneumonitis). J Am Acad Dermatol 2011; 64: 1154-8.
30. McGregor JM, Barker JN, MacDonald DM,. Pulmonary capillary leak syndrome complicating generalized pustular psoriasis: possible role of cytokines. Br J Dermatol 1991; 125: 472-4.
31. Sadeh JS, Rudikoff D, Gordon ML, et al,. Pustular and erythrodermic psoriasis complicated by acute respiratory distress syndrome. Arch Dermatol 1997; 133: 747-50.
32. Doval IG, Peteiro C, Toribio J,. Acute respiratory distress syndrome and generalized pustular psoriasis: another case report. Arch Dermatol 1998; 134: 103.
33. Craig JA,. Jaundice in acute pustular psoriasis. Br Med J 1974; 3: 43.
34. Aronsson A, Nilsson A,. Pustular psoriasis of v. Zumbusch type associated with recurring cholestatic jaundice. Acta Derm Venereol 1986; 66: 164-7.
35. Warren DJ, Winney RJ, Beveridge GW,. Oligaemia, renal failure, and jaundice associated with acute pustular psoriasis. Br Med J 1974; 2: 406-8.
36. Marrakchi S, Guigue P, Renshaw BR, et al,. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med 2011; 365: 620-8.
37. Navarini AA, Valeyrie-Allanore L, Setta-Kaffetzi N, et al,. Rare variations in IL36RN in severe adverse drug reactions manifesting as acute generalized exanthematous pustulosis. J Invest Dermatol 2013; 133: 1904-7.